Ginkgo to acquire Zymergen for ~$300M all-stock; Zymergen holders get 0.9179 DNA shares

Ginkgo Bioworks Holdings, Inc.

Deal valued at ~$300M market cap; fixed exchange ratio of 0.9179 Ginkgo shares per Zymergen share.
Zymergen stockholders will own 5.25% of pro forma combined company after transaction close.
Voting agreements from holders of ~40% of Zymergen shares to vote in favor of the merger.
Integration expected to accelerate Ginkgo's platform; Zymergen to evaluate strategic alternatives for Advanced Materials and Drug Discovery.
Transaction subject to regulatory approvals, Zymergen stockholder vote, and other conditions; expected close by Jan 24, 2023 with extension options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.